

# **Data Sheet**

 $\begin{tabular}{lll} \mbox{Product Name:} & Latrunculin B \\ \mbox{Cat. No.:} & CS-0022006 \\ \mbox{CAS No.:} & 76343-94-7 \\ \mbox{Molecular Formula:} & C_{20}\mbox{H}_{29}\mbox{NO}_{5}\mbox{S} \\ \end{tabular}$ 

Molecular Weight: 395.51

Target: Fungal

Pathway: Anti-infection

Solubility: 10 mM in DMSO

## **BIOLOGICAL ACTIVITY:**

Latrunculin B, an antimicrobial marine alkaloid, is an **actin polymerization** inhibitor. Latrunculin B regulates pulmonary vein electrophysiological characteristics and attenuates stretch-induced arrhythmogenesis. Antifungal and antiprotozoal activity<sup>[1][2]</sup>. *In Vitro:* Latrunculin B displays growth inhibition of HeLa cells with an IC<sub>50</sub> value of 1.4 μM<sup>[1]</sup>.

Latrunculin B modulates electrophysiological characteristics and arrhythmogenesis in pulmonary vein cardiomyocytes. Latrunculin B (100 nM) decreases the spontaneous electrical activity by 16±4% in pulmonary vein (PV) preparations. Latrunculin B (100 nM) decreases the late Na<sup>+</sup> current, L-type Ca<sup>2+</sup> current, Na<sup>+</sup>/Ca<sup>2+</sup> exchanger current, and stretch-activated BKCa current in PV cardiomyocytes. Latrunculin B reduces the transient outward K<sup>+</sup> current and ultra-rapid delayed rectifier K<sup>+</sup> current, but increases the delayed rectifier K<sup>+</sup> current in isolated PV cardiomyocytes. Latrunculin B (100 nM) decreases intracellular Ca<sup>2+</sup> transient and sarcoplasmic reticulum Ca<sup>2+</sup> content in PV cardiomyocytes. Latrunculin B attenuates stretch-induced increased spontaneous electrical activity and trigger activity<sup>[2]</sup>.

#### References:

[1]. Diaa T A Youssef, et al. Magnificines A and B, Antimicrobial Marine Alkaloids Featuring a Tetrahydrooxazolo[3,2-a]azepine-2,5(3H,6H)-dione Backbone from the Red Sea Sponge *Negombata magnifica*. Mar Drugs. 2021 Apr 12;19(4):214.

[2]. Yen-Yu Lu, et al. Latrunculin B modulates electrophysiological characteristics and arrhythmogenesis in pulmonary vein cardiomyocytes. Clin Sci (Lond). 2016 May;130(9):721-32.

## **CAIndexNames:**

 $2-Thiazolidinone,\ 4-[(1R,4Z,8Z,10S,13R,15R)-15-hydroxy-5,10-dimethyl-3-oxo-2,14-dioxabicyclo[11.3.1]heptadeca-4,8-dien-15-yl]-,\ (4R)-10-dimethyl-3-oxo-2,14-dioxabicyclo[11.3.1]heptadeca-4,8-dien-15-yl]-,\ (4R)-10-dimethyl-3-dioxabicyclo[11.3.1]heptadeca-4,8-dien-15-yl]-,$ 

# **SMILES:**

 $O=C1SC[C@@H]([C@]2(O)O[C@]3([H])CC[C@H](C)/C=C\\CC/C(C)=C\\C(O[C@@](C3)([H])C2)=O)\\N1$ 

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr., Suite Q., Monmouth Junction, NJ 08852, USA

Page 1 of 1 www.ChemScene.com